The world’s first successful treatment of babies transplanting liver cells made from ES cells

World’s first transplantation of liver cells made from ES cells Baby Treatment Success May 21 4:16

k10012438171_202005211008_202005211010.mp4
Liver cells made from ES cells that can be transformed into cells in various tissues and organs of the body have been successfully transplanted to treat incurable babies, the National Center for Adult Health Research has announced. According to the center, it is the first transplantation of cells made from cells in Japan, and the first in the world to be transplanted into the liver.

In October last year, a medical team led by Akiya Fukuda, director of the National Center for Organ Transplantation, announced that he had transplanted liver cells made from ES cells to babies on the sixth day of birth of urea cycle abnormalities.

Urea cycle abnormality is an intractable disease that can not break down ammonia because certain enzymes do not work in the liver, and can lead to death, and the root treatment is only liver transplantation.

However, in the case of babies, liver transplants were not available until about three to five months after birth, when their weight grew to about six kilograms, so treatment during that time was a challenge.

The medical team transplanted 190 million liver cells made from ES cells to reach the blood vessels of the baby’s liver through their blood vessels, so that the concentration of ammonia in the blood became normal and they were able to leave the hospital nine weeks later.

The baby then underwent a liver transplant from his father in March and is growing well.

According to the center, this is the first time in Japan that cells made from CELLS have been transplanted into the liver, and the medical team hopes to make it a widely available treatment by performing more transplants during this year as a clinical trial to confirm safety and efficacy.

The director of the Kasahara Group Organ Transplant Ation Center said, “We performed surgery after more than a year of research on cells. I think it is important to work with iPS cells.”